ESTRO 2024 - Abstract Book

S2193

Clinical - Upper GI

ESTRO 2024

Gabriele 18 , Mariacristina Di Marco 19 , Nicola Simoni 20 , Johnny Ma 1,5 , Lidia Strigari 21 , Renzo Mazzarotto 22 , Alessio Giuseppe Morganti 1,5 1 Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 2 Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. 3 UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. 4 Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy. 5 Department of Medical and Surgical Sciences - DIMEC, University of Bologna, Bologna, Italy. 6 Radiation Oncology Unit, Gemelli Molise Hospital-Università Cattolica del Sacro Cuore, Campobasso, Italy. 7 Radiation Oncology Department, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy. 8 Medical Physics Unit, Gemelli Molise Hospital-Università Cattolica del Sacro Cuore, Campobasso, Italy. 9 Radiation Oncology, Public Hospital, Klagenfurt, Austria. 10 Radiotherapy Unit, Ospedale Belcolle, Viterbo, Italy. 11 Institute of Oncology Vojvodina, Sremska Kamenica, Medical Faculty, University of Novi Sad, Novi Sad, Serbia. 12 Radiotherapy Unit, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. 13 Radiation Oncology, Mater Olbia Hospital, Olbia, Italy. 14 Department of Radiotherapy, Università Campus Biomedico, Rome, Italy. 15 Department of Radiotherapy, Azienda Ospedaliero Universitaria Careggi (AOUC), Università di Firenze, Firenze, Italy. 16 Department of Radiotherapy, IRCCS AOU San Martino – IST Genova, Genova, Italy. 17 Radiotherapy Unit, Azienda Ospedaliera San Gerardo, Monza, Italy. 18 Fondazione del Piemonte per l'Oncologia (FPO), IRCCS Candiolo, Department of Radiotherapy, Candiolo, Italy. 19 Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 20 Radiotherapy Unit, Azienda Ospedaliera Universitaria, Parma, Italy. 21 Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 22 Radiotherapy Unit, Universital Hospital, Verona, Italy

Purpose/Objective:

Pancreatic cancer is associated with a dismal prognosis, and radical surgery with tumor-free margins remains the primary approach for long-term survival. However, a subset of patients with unresectable locally advanced pancreatic cancer (LAPC) experiences unexpected long-term survival, despite the general poor prognosis. The underlying reasons for this phenomenon are not yet well understood. To address this, we conducted a secondary analysis of the multicenter observational study PAULA-1, focusing specifically on long term survivors of LAPC.

Material/Methods:

We included LAPC patients without distant metastases who were managed with chemotherapy (CHT), stereotactic body radiotherapy (SBRT), or concurrent chemoradiation (CRT), and who did not undergo surgical resection either before or after their treatment. This analysis drew from data collected at 15 different institutions. Long-term survivors, defined as patients with an overall survival exceeding 60 months, were the focus of this investigation.

Results:

Our analysis encompassed 419 patients, and among them, we identified 7 long-term survivors (refer to Table 1 for details). Four of these patients were treated with CRT, receiving a total radiation dose of 50.4 Gy in 1.8 Gy/fraction. Two patients underwent CRT with the same total radiation dose but with an additional sequential